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 Objective: To compare adherence and persistence to typical versus atypical antipsychotics 
and between speciﬁ  c atypical agents in the usual care of schizophrenia and to examine the 
association between adherence and persistence.
Method: Data were drawn from a 3-year prospective, nonrandomized, noninterventional study 
of schizophrenia conducted during 1997–2003. Initiators on haloperidol, risperidone, olanzapine, 
quetiapine, and clozapine with at least 1 year of follow-up were included (n = 878). Adherence 
(Medication Possession Ratio, MPR) and persistence (time to all-cause medication discon-
tinuation) were assessed using medical record prescription information. Analyses employed 
multivariate statistics adjusted for group differences.
Results: Overall, 58% of the patients were deemed adherent (MPR  80%). Adherence rates 
were higher: for atypical (59.4%) than typical antipsychotics (34.5%, p   0.001), for clozapine 
(77%) than each comparator excluding olanzapine (p   0.01), and for olanzapine (64%) than 
risperidone (57%, p = 0.027) and quetiapine (52%, p = 0.019). Differences between risperidone 
and quetiapine were not statistically signiﬁ  cant. Adherence and persistence were highly cor-
related (r = 0.957, p   0.001).
Conclusion: In the usual care of schizophrenia, medication adherence and persistence appear 
to be highly correlated and to signiﬁ  cantly differ between typical and atypical antipsychotics 
and among atypical agents. The choice of antipsychotic may play a meaningful role in patients’ 
adherence to and persistence with antipsychotic medications.
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Introduction
In the treatment of schizophrenia, poor adherence with antipsychotic medication is 
known to raise personal burden and economic cost (Fenton et al 1997) by increasing 
the risk of relapse, hospitalizations (Fenton et al 1997; Valenstein et al 2002; Gilmer 
et al 2004; Weiden et al 2004; Ascher-Svanum et al 2006a), and poorer functional 
outcomes, including arrests and violent behaviors (Swanson et al 2004a, b; Ascher-
Svanum et al 2006a). The risk of nonadherence with antipsychotic regimens is affected 
by factors that are broadly categorized as patient, environment, and treatment-related 
risk factors (Kampman and Lehtinen 1999). Among the treatment-related risk factors 
is choice of the antipsychotic agent.
Differences between typical and atypical antipsychotics have been extensively 
studied and are the topic of ongoing debate whether some atypical antipsychotics 
are more effective than others and whether atypicals are more effective than typical 
antipsychotics (Geddes et al 2000; Rosenheck et al 2003; Jones et al 2006; Rosenheck 
2006). When compared on level of medication adherence, schizophrenia patients treated 
with typical antipsychotics were often found (Cabeza et al 2001; Svarstad et al 2001; Patient Preferences and Adherence 2008:2 68
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Al-Zarkawi et al 2003; Menzin et al 2003; Mojtabai et al 
2003; Opolka et al 2003; Garcia-Gibson et al 2004), but not 
always (Dolder et al 2002; Diaz et al 2004; Gilmer et al 2004; 
Valenstein et al 2004), to have poorer adherence compared to 
patients treated with atypicals. When comparing adherence 
between atypical agents, several studies reported greater 
adherence to speciﬁ  c atypical antipsychotics versus other 
atypicals (eg, to olanzapine vs risperidone) (Garcia-Cabeza 
et al 2001; Zhao et al 2002; Opolka et al 2003; Rascati 
et al 2003; Diaz et al 2004; Gibson et al 2004), whereas 
other studies did not (Dolder et al 2002; Gilmer et al 2004; 
Valenstein et al 2004).
In contrast with the inconclusive ﬁ  ndings on differential 
adherence to various antipsychotics, previous ﬁ  ndings on 
medication persistence with antipsychotics have been rela-
tively consistent, often showing better persistence on atypical 
than typical antipsychotics (Revicki et al 1999; Glick and Berg 
2002; Leucht et al 2003; Lieberman et al 2003; Dossenbach 
et al 2004; Kemmler et al 2005; Ascher-Svanum et al 2006b; 
Tiihonen et al 2006; Tunis et al 2006; Beasley et al 2007; 
Cooper et al 2007; Haro et al 2007) and better persistence 
with a speciﬁ  c atypical (olanzapine) when compared to 
other atypicals such as risperidone, quetiapine, ziprasi-
done, and aripiprazole (PhRMA aripiprazole; Gilbody 
et al 2000; Ren et al 2002; Bagnall et al 2003; Santarlasci
and Messori 2003; Dossenbach et al 2004; Pelagotti et al
2004; Simpson et al 2004; Breier et al 2005; Mudge et al 2005; 
Kinon et al 2006a, b; Tunis et al 2006; Cooper et al 
2007; Haro et al 2007; Jayaram et al 2007; Mullins et al 
2007; Strom et al 2007).
Differences in persistence among atypical antipsychot-
ics were also observed in the NIMH-sponsored CATIE 
schizophrenia study (Lieberman et al 2005; McEvoy et al 
2006; Stroup et al 2006), a large, 18-month, double-blind, 
randomized study comparing 5 antipsychotics: a medium 
potency typical antipsychotic (perphenazine) and 4 atypi-
cal antipsychotics (olanzapine, risperidone, quetiapine, 
ziprasidone). Persistence, as measured by time to all-cause 
medication discontinuation, was assumed to reﬂ  ect a med-
ication’s efﬁ  cacy, safety, and tolerability from both patient 
and clinicians’ perspectives (Stroup et al 2003; Lieberman 
et al 2005). The primary phase of the CATIE, Phase 1, found 
signiﬁ  cantly longer time to all-cause medication discontinu-
ation on olanzapine compared to risperidone and quetiapine. 
Treatment duration on olanzapine did not signiﬁ  cantly differ 
from ziprasidone or perphenazine as the initially signiﬁ  cant 
differences favoring olanzapine turned nonsigniﬁ  cant follow-
ing adjustment for multiple comparisons. In a second phase 
of CATIE (phase 2E; McEvoy et al 2006), which included 
patients who discontinued Phase 1 due to lack of medication 
efﬁ  cacy, persistence in therapy was signiﬁ  cantly longer for 
clozapine than quetiapine or risperidone, but not compared 
to olanzapine. Furthermore, in CATIE phase 2T (Stroup et al 
2006), which included patients who discontinued Phase 1 due 
to medication intolerability or lack of efﬁ  cacy, persistence 
in therapy was longer for patients treated with risperidone 
and olanzapine compared to quetiapine and ziprasidone. In 
addition, for patients who discontinued their previous anti-
psychotic because of inefﬁ  cacy, persistence on olanzapine 
therapy was longer than for quetiapine and ziprasidone and 
for risperidone longer than quetiapine.
Although adherence and persistence with antipsychotics 
have been extensively examined using multiple methodolo-
gies, they have been studied separately in different patient 
populations (Cooper et al 2007). As a result, no information 
is available on the potential correspondence between patients’ 
adherence and persistence on the same medications in the 
treatment of schizophrenia. The only study that assessed 
both persistence and adherence with atypical antipsychot-
ics in the same population (Cooper et al 2007) did not 
assess concordance between the adherence and persistence 
measures and focused on adherence with speciﬁ  c atypical 
antipsychotics among patients who were deemed persistent 
with any atypical antipsychotic regimen. That study found 
differential persistence among the atypicals (greater likeli-
hood of persistence with clozapine and olanzapine than with 
risperidone), but no differentiation on adherence among the 
persistent patients.
The present study aimed to expand on previous research 
and assess differences in medication adherence and persis-
tence to typical versus atypical antipsychotics and to speciﬁ  c 
atypical agents in the usual care of patients with schizophre-
nia. A secondary objective was to examine the concordance 
between patients’ adherence and persistence with the same 
antipsychotics. Using prescription data from a large, 3-year 
prospective, naturalistic, nonrandomized, noninterventional, 
multisite study of patients treated for schizophrenia in the 
US, we identiﬁ  ed patients who were initiated on typical 
(haloperidol) or atypical (clozapine, olanzapine, risperidone, 
or quetiapine) antipsychotics at any time in the study and 
had been followed up for at least 1 year post-initiation. We 
expected adherence and persistence to be highly interrelated, 
and based on previous research on persistence with antipsy-
chotics in the treatment of schizophrenia (Gilbody et al 2000; 
Ren et al 2000; Bagnall et al 2003; Lieberman et al 2003; 
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et al 2004; Simpson et al 2004; Dossenbach et al 2004; Breier 
et al 2005; Lieberman 2005; Stroup 2006; McEvoy 2006; 
Kinon et al 2006a, b; Tunis et al 2006; Tiihonen et al 2006; 
Haro et al 2007; Cooper et al 2007; Mullins et al 2007) we 
hypothesized that the 4 atypicals are superior to the typical 
antipsychotic haloperidol on persistence and adherence and 
that clozapine and olanzapine therapy would differentiate 
themselves among the 4 atypical agents with greater adher-
ence and persistence.
Methods
Data source
We used data from the Lilly-sponsored Schizophrenia Care 
and Assessment Program (US-SCAP), a large (n = 2327), 
3-year, naturalistic, prospective, nonrandomized nonin-
terventional study in the US that was conducted between 
7/1997 and 9/2003 (Faries et al 2005; Ascher-Svanum et al 
2004, 2006a, b). The goal of US-SCAP was to understand 
the treatment of patients with schizophrenia in “real world” 
settings. Approximately 400 patients at each of the study’s 
6 regional sites were enrolled. All patients were diagnosed 
with schizophrenia, schizoaffective, or schizophreniform 
disorders based on DSM-IV criteria and were at least 18 years 
of age. Patients were excluded if they were unable to provide 
informed consent or had participated in a clinical drug trial 
within 30 days prior to enrollment. Of 3332 patients who met 
inclusion criteria, 765 (23.0%) refused, and 240 (7.2%) were 
not enrolled due to other reasons. Most enrollees completed 
1 year of follow-up (78.1%), with fewer patients completing 
2 years (69.6%) and 3 years (65.2%).
Enrollment was not contingent upon being treated with 
a speciﬁ  c antipsychotic or with any medication. Patients 
could continue with medications they were prescribed prior 
to enrollment for as long as necessary, and decisions about 
changes in medications during the study, if any, were made 
by physicians and their patients as occurs in usual practice.
Patients were enrolled from 6 states (California, Colorado, 
Connecticut, Florida, Maryland, and North Carolina) and 
represented treatment in diverse systems of care including 
community mental health centers, university health care 
systems, the Department of Veterans Affairs Health Services 
(VA), and community and state hospitals. Institutional 
Review Board (IRB) approval was received at each regional 
site, and informed consent was received from all patients. 
Further details about US-SCAP are available elsewhere 
(Faries et al 2005; Ascher-Svanum et al 2006a, b).
The present study included patients who were initiated at 
any time during the 3-year study on haloperidol, clozapine, 
risperidone, olanzapine, or quetiapine in standard oral 
formulation. Treatment group membership was based on the 
ﬁ  rst initiated medication at any time in the study. These patients 
did not receive the index medication in the 60 days prior to 
initiation and had at least 1 year of follow-up after initiation. 
Reﬂ  ecting usual clinical practice, patients could be augmented 
with other typical and/or atypical antipsychotics (antipsychotic 
polypharmacy), in any formulation at any time per physician’s 
decision. Patients initiated on ziprasidone or aripiprazole were 
excluded from the analysis due to small sample size.
Measures
Interviews with the patients at enrollment provided 
information about socio-demographic characteristics and 
psychiatric history. Starting at enrollment, medical records 
were systematically abstracted for each prior 6-month 
interval for every patient using a medical resource abstraction 
form that was developed for this study.
Patients’ medical records provided information about 
each psychiatric hospitalization (admission and discharge 
dates) and about prescribed psychiatric medication (medica-
tion name, dose, frequency, start and stop dates, and route of 
administration). Patients were queried about use of medica-
tions and other psychiatric resources outside of those provided 
at their regular treatment site. When this occurred, systematic 
efforts were made to abstract out-of-site medical records.
Consistent with prior research (Valenstein et al 2002; 
Weiden et al 2004), adherence was assessed with the Medica-
tion Possession Ratio (MPR), the percent of total cumulative 
days with the index medication during the 365 days following 
its initiation. Higher values indicate better adherence with 
the prescribed antipsychotic medication. Poor adherence, 
often deﬁ  ned as MPR  80%, was previously found to be 
associated with a high risk of psychiatric hospitalizations 
(Valenstein et al 2002; Thieda et al 2003; Ascher-Svanum 
et al 2006a), emergency services, arrests, violent behaviors, 
substance use, and other unfavorable outcomes (Thieda et al 
2003; Ascher-Svanum et al 2006a). Adherence was deﬁ  ned 
as MPR  80%, a threshold used in past research to assess 
adherence with antipsychotics in the treatment of schizo-
phrenia (Dolder et al 2002; Gilmer et al 2004; Valenstein 
et al 2002, 2004; Elbogen et al 2005). The MPR was used 
to calculate mean adherence rates (continuous MPR) and 
the proportion of adherent patients (MPR  80%) in each 
treatment group.
Although MPR is commonly used to quantify medica-
tion use in pharmacy claims databases, the MPR in this 
study was based on prescription information in medical Patient Preferences and Adherence 2008:2 70
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records. Since no pharmacy claim data were collected in 
US-SCAP, the rate of prescription ﬁ  ll is unknown. However, 
prior research in this population (Svarstad et al 2001) has 
shown a high level of correspondence between medication 
prescription in medical records and pharmacy ﬁ  ll rate.
Persistence with the index antipsychotic drug was deﬁ  ned 
as the time to medication discontinuation for any cause and 
calculated as the number of consecutive days from initia-
tion of the index drug to the start of the ﬁ  rst medication gap 
of  30 days during the 1-year following initiation (Ren 
et al 2002; Zhao et al 2002; Mojtabai et al 2003; Gibson 
et al 2004). A gap could have resulted from any number of 
events, including switching to another drug or discontinu-
ation of the drug. Although several studies have used the 
criterion of  14 consecutive days without medication as an 
indicator of drug discontinuation, we took a more conserva-
tive approach and used a larger medication gap size. Past 
research has shown consistent ﬁ  ndings when using 14 or 30 
days to deﬁ  ne medication discontinuation in the treatment 
of schizophrenia (Ascher-Svanum et al 2006b). In addition 
to mean time to medication discontinuation, the proportion 
of patients completing at least 1 year of treatment on the 
initiated antipsychotic was also measured.
Statistical analysis
Group comparisons on socio-demographic and treatment 
characteristics prior to initiation on the “index” antipsychotic 
medication were made using chi-square tests for categorical 
variables and ANOVA for continuous variables. To compare 
medication groups on adherence, we performed linear and 
logistic regression models after square root transformation of 
the MPR due to its skewed distribution (Box and Cox 1964). 
These analyses controlled for patient socio-demographics 
(age, sex, ethnicity), illness duration, and treatment variables 
on which the treatment groups were found to signiﬁ  cantly dif-
fer during the 2 months prior to initiation of the index medi-
cation (psychiatric hospitalization [yes/no] and use [yes/no] 
of: oral antipsychotics, depot typical antipsychotics, mood 
stabilizers, and antipsychotic polypharmacy). To check the 
robustness of the ﬁ  ndings, analyses were repeated controlling 
also for potential “time period bias” in the regression analysis, 
because atypical antipsychotics were introduced in the US 
over several years. To that end, we calculated for each patient 
the time (days) elapsed between the study start (7/1/1997) 
and the initiation date on the index medication.
Treatment group comparisons on the mean continuous 
MPR, proportion of adherent patients per MPR  80%, 
mean time to medication discontinuation for any cause, and 
proportion of patients completing at least 1 year on the index 
medication were performed for the typical (haloperidol) ver-
sus atypicals (clozapine, risperidone, olanzapine, quetiapine, 
combined), for the typical versus each of the 4 atypicals, and 
pair-wise comparisons between the atypicals. To compare 
medication groups on the proportion of adherent patients 
(MPR  80%), we used logistic models with adjustments 
for covariates noted above. To assess the robustness of the 
ﬁ  ndings, we repeated the latter analysis using 7 other adher-
ence thresholds that dichotomized the MPR into adherent 
and nonadherent, including MPR  60%, 65%, 70%, 75%, 
85%, 90%, and 95%.
To assess the concordance between the adherence and 
persistence measures, we calculated Pearson product-
moment correlation between the continuous MPR measure 
and time (days) to all-cause medication discontinuation. 
Treatment group comparisons on persistence levels employed 
Cox Proportional Hazard Model, adjusted for covariates used 
in the adherence analyses.
Although all patients have undergone clinical assessments 
with standard measures at enrollment and every 12 months 
thereafter, these assessments were not set to coincide with 
the time of initiation or discontinuation of any drug. These 
clinical measures were not used in this study to control for 
treatment group differences, because the assessments did not 
reﬂ  ect patients’ clinical status at the time of initiation on the 
medication. All statistical tests were 2-tailed, and signiﬁ  cance 
was set at alpha of 0.05.
Results
Patient characteristics
This study included patients (n = 878) who were initiated 
on haloperidol (n = 110), clozapine (n = 74), risperidone 
(n = 235), olanzapine (n = 347), and quetiapine (n = 112). At 
the time of initiation on the index medication, the treatment 
groups signiﬁ  cantly differed on age, ethnicity, illness dura-
tion, and on the following variables in the 60 days prior to 
initiation on the index antipsychotic: psychiatric hospitaliza-
tion, use of antipsychotics in oral formulation, antipsychot-
ics in depot formulation, antipsychotic polypharmacy, and 
mood stabilizers (Table 1). Treatment groups also differed 
on time to initiation on the index medication from the date 
of the study start. Expectedly, quetiapine-treated patients 
had longer time to medication initiation since quetiapine 
was launched in the US later (1997) than clozapine (1990), 
risperidone (1994), and olanzapine (1996). The mean daily 
doses (SD) of the index antipsychotics were: 8.8 mg (6.8 mg) 
for haloperidol, 368.9 mg (164.2 mg) for clozapine, 4.1 mg Patient Preferences and Adherence 2008:2 71
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(2.4 mg) for risperidone, 13.7 mg (7.3 mg) for olanzapine, 
and 331.6 mg (210.9 mg) for quetiapine.
Adherence
Mean MPR
The mean MPR for all patients was 70.9%. As presented in 
Table 2, the mean MPR was signiﬁ  cantly higher for patients 
treated with atypical antipsychotics (MPR = 73.6%) com-
pared to haloperidol (MPR = 52.0%, p   0.001) and for 
patients treated with each atypical compared to haloperidol 
(p   0.001). Signiﬁ  cantly higher mean adherence rate was 
found for patients treated with clozapine (MPR = 83.5%) 
compared to risperidone (MPR = 70.0%, p = 0.024) and que-
tiapine (MPR = 66.2%, p = 0.022). Signiﬁ  cantly higher mean 
adherence rate was found for patients treated with olanzapine 
(MPR = 76.3%) compared to risperidone (MPR = 70.0%, 
p = 0.008) and quetiapine (MPR = 66.2%, p = 0.005). Dif-
ferences between risperidone and quetiapine (p = 0.538) and 
between clozapine and olanzapine (p = 0.648) therapy were 
not statistically signiﬁ  cant.
Proportion of adherent patients
Overall, 58% of the patients were deemed adherent 
(MPR  80%). A signiﬁ  cantly greater proportion of atypical 
antipsychotic-treated patients were adherent compared to 
the haloperidol-treated group (61.1% vs 34.5%, p   0.001) 
(Table 2). Among the atypical agents, a signiﬁ  cantly larger 
proportion of clozapine-treated patients were adherent 
compared to risperidone (77.0% vs 56.6%, p   0.01) and 
quetiapine (77.0% vs 51.8%, p   0.01), but not compared 
to olanzapine (77.0% vs 63.7%, p   0.05). A signiﬁ  cantly 
larger proportion of olanzapine-treated patients were 
adherent compared to patients treated with risperidone 
(63.7% vs 56.6%, p = 0.027) and quetiapine (63.7% vs 
51.8%, p = 0.019). The difference between risperidone and 
quetiapine-treated patients was not statistically signiﬁ  cant 
(56.6% vs 51.8%, p = 0.305).
Sensitivity analyses
To assess robustness of the ﬁ  ndings, we repeated the analysis 
using 7 additional MPR thresholds to deﬁ  ne adherence with 
Table 1 Patient characteristics by treatment groupa
Characteristic Haloperidol  Risperidone  Olanzapine  Quetiapine  Clozapine
 n  = 110  n = 235  n = 347  n = 112  n = 74
Age, mean (SD)b  37.9 (9.6)  41.8 (12.5)  43.3 (10.8)  40.6 (11.2)  38.6 (8.9)
Illness duration in years, mean (SD)b  18.5 (10.9)  21.3 (12.6)  23.3 (11.8)  19.6 (11.1)  20.0 (10.1)
Male  (%)  55.5 54.9 61.1 47.3 62.2
Race (%)b      
White  30.9 46.8 49.9 50.9 62.2
Black  48.2 38.7 38.3 35.7 23.0
Other  20.9 14.5 11.8 13.4 14.9
High school education or less (%)  59.1  69.2  65.3  74.6  73.0
Diagnosis  (%)      
Schizoaffective  34.6 32.8 32.3 39.3 35.1
Schizophrenia,  paranoid  36.4 38.7 42.9 32.1 40.5
Schizophrenia,  undifferentiated  19.1 16.2 15.9 15.2 18.9
Other 10.0  12.3  8.9  13.4  5.41
Health  Insurance  (%)      
Medicaid/Medicare/Medicaid and Medicare  76.9  79.8  81  83.6  86.5
CHAMPUS (Department of Defense)  4.6  5.6  7.9  2.7  5.4
Privately  insured  5.6 3.9 2.6 2.7 1.4
Other  1.9 1.3 0.6 1.8 1.4
No  insurance  11.1  9.4 7.9 9.1 5.4
Time to initiation on index medication, mean  515.6 (340.9)  640.5 (327.1)  599 (333.1)  834.3 (315.3)  618.7 (349.4)
days (S.D.)b
Prior psychiatric hospitalization (%)b,c  38.2 22.6 17.0 15.2 35.1
Prior medication Usec      
Oral antipsychoticsb  43.6 70.6 71.5 88.4 82.4
Typical depot antipsychoticsb  33.6 16.6 21.3 13.4 21.6
Mood stabilizersb  29.1 20.9 31.7 37.5 37.8
Antipsychotic polypharmacyb  8.2 11.1  6.1 24.1  24.3
aPercentages listed unless otherwise speciﬁ  ed.
bSigniﬁ  cant groups difference at p   0.05.
cDuring the 60 days prior to initiation on the index drug. Patient Preferences and Adherence 2008:2 72
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cutoff values ranging from MPR  60% to MPR  95% in 
5% increments. Table 3 presents the proportion of adherent 
patients by treatment group and the associated p values from 
the logistic regression, demonstrating the robustness of the 
ﬁ  ndings across the 8 variations on the deﬁ  nition of adher-
ence. Results were also essentially unchanged when the 
analyses were repeated with additional control for potential 
“time period bias”.
Persistence
Mirroring the adherence-related ﬁ  ndings (Table 2), persis-
tence, as measured by time to all-cause medication discontinu-
ation (days), was signiﬁ  cantly shorter for haloperidol (173.9) 
than for the combined atypical antipsychotic treatment groups 
(260.7, p   0.001) and differed between the atypical antipsy-
chotics in descending order: clozapine (305.46), olanzapine 
(271.66), risperidone (245.07), and quetiapine (230.19). The 
same descending order was found when using the proportion 
of patients completing at least 1 year of treatment on the 
initiated medication: clozapine (71.6%), olanzapine (56.5%), 
risperidone (48.5%), quetiapine (45.5%), and haloperidol 
(22.7%). The proportion of patients completing at least 1 year 
of treatment on the index medication was signiﬁ  cantly higher 
for patients treated with atypicals, in aggregate, compared to 
the typical (p   0.001), and for clozapine compared to halo-
peridol (p   0.001), risperidone (p = 0.002), and quetiapine 
(p = 0.004), but not compared to olanzapine (p = 0.052). 
The olanzapine group had a signiﬁ  cantly higher treatment 
completion rate compared to haloperidol (p   0.001), risperi-
done (p = 0.033), and quetiapine (p = 0.029). The risperidone 
group had signiﬁ  cantly higher treatment completion rates 
than haloperidol (p   0.001), but not compared to quetiapine 
(p = 0.313). The quetiapine signiﬁ  cantly differed only from 
haloperidol (p = 0.015).
Using the Cox Proportional Hazard Model, the haloperidol-
treated group was found to be more likely to discontinue 
the medication compared to the atypical-treated patients 
(hazard ratio [HR] = 2.31, 95% conﬁ  dence interval [CI] 
1.78–3.01, p   0.001). The olanzapine-treated patients were 
more likely to discontinue than clozapine (HR = 1.65, 95% 
CI 1.01–2.71, p = 0.047). The risperidone-treated patients 
were more likely to discontinue than clozapine (HR = 2.09, 
Table 2 Adherence and persistence in the 1-year post initiation by treatment group
Treatment group  Adherence    Persistence
  Mean (SD)   Proportion adherent  Mean(SD) time to all-cause  Proportion
 MPR%  (MPR    80%) discontinuation  persistent
Atypicals, combined vs HAL  73.6 (35.0)c 61.1c 260.7  (136.0)c 53.9c
 52.0  (37.9)  34.5  173.9  (144.5)  22.7
CLO vs OLZ  83.5 (31.6)  77  305.46 (114.4)  71.6
  76.3 (33.3)  63.7  271.7 (129.7)  56.5
CLO vs RIS  83.5 (31.6)a 77b 305.46  (114.4)b 71.6b
  70.0 (36.5)  56.6  245.1 (142.2)  48.5
CLO vs QUE  83.5 (31.6)a 77b 305.46  (114.4)b 71.6b
 66.2  (37.0)  51.8  230.2  (145.2)  45.5
CLO vs HAL  83.5 (31.6)c 77c 305.46  (114.4)c 71.6c
 52.0  (37.9)  34.5  173.9  (144.5)  22.7
OLZ vs RIS  76.3 (33.3)b 63.7a 271.7  (129.7)a 56.5a
  70.0 (36.5)  56.6  245.1 (142.2)  48.5
OLZ vs QUE  76.3 (33.3)b 63.7a 271.7  (129.7)b 56.5a
 66.2  (37.0)  51.8  230.2  (145.2)  45.5
OLZ vs HAL  76.3 (33.3)c 63.7c 271.7  (129.7)c 56.5c
  52.0 (37.9)  34.5  173.9 (144.5)  22.7
RIS vs QUE  70.0 (36.5)  56.6  245.1 (142.2)  48.5
  66.2 (37.0)  51.8  230.2 (145.2)  45.5
RIS vs HAL  70.0 (36.5)c 56.6b 245.1  (142.2)c 48.5c
  52.0 (37.9)  34.5  173.9 (144.5)  22.7
QUE vs HAL  66.2 (37.0)b 51.8a 230.2  (145.2)a 45.5a
 52.0  (37.9)  34.5  173.9  (144.5)  22.7
Sample size: Haloperidol n = 110; OLZ n = 347; RIS n = 235; QUE n = 112; CLO n = 74.
Adherent deﬁ  ned as MPR   80%; Persistent deﬁ  ned as completing 1 year of treatment on the index drug.
aSigniﬁ  cant groups difference at p   0.05.
bSigniﬁ  cant groups difference at p   0.01.
cSigniﬁ  cant groups difference at p   0.001.
Abbreviations: MPR, medication possession ratio; CLO, clozapine; HAL, haloperidol; OLZ, olanzapine; QUE, quetiapine; RIS, risperidone.Patient Preferences and Adherence 2008:2 73
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95% CI 1.29–3.40, p = 0.003) and olanzapine-treated patients 
(HR = 1.35, 95% CI 1.04–1.74, p = 0.023). The quetiapine-
treatment group was more likely to discontinue medication 
compared to clozapine (HR = 2.24, 95% CI 1.29–3.88, 
p = 0.004) and olanzapine-treated patients (HR = 1.55, 95% 
CI 1.09–2.20, p = 0.014). Hazard ratios were statistically 
signiﬁ  cant except for the comparison between risperidone 
and quetiapine (HR = 1.21, 95% CI 0.86–1.70, p = 0.285).
Adherence and persistence
The MPR-based adherence measure was highly and sig-
niﬁ  cantly correlated with the persistent measure – time to 
all-cause medication discontinuation (r = 0.957, n = 878, 
p   0.001).
Discussion
In this large, prospective, naturalistic, nonrandomized study 
of schizophrenia patients, as in several other studies (Fenton 
et al 1997; Cramer and Rosenheck 1998; Gilmer et al 2004), 
only about half of the patients (58%) were found to be adher-
ent to antipsychotic regimens. Adherence was, however, 
especially poor for patients treated with the typical antipsy-
chotic haloperidol. Only 35% of the patients treated with 
haloperidol were found to be adherent compared to 61% of 
the patients treated with atypicals. The atypicals were not all 
alike, and among the studied atypicals, clozapine therapy was 
associated with highest rate of adherence (77%) followed by 
olanzapine (64%), risperidone (57%), and quetiapine (52%) 
therapy. Although rates of adherence with atypicals appear 
signiﬁ  cantly higher than with the typical antipsychotic, these 
are still suboptimal adherence rates, as a large proportion of 
the patients remain poorly adherent with their medication 
regimens.
In addition to replicating previous ﬁ  ndings (Svarstad 
et al 2001; Al-Zarkawi et al 2003; Menzin et al 2003; 
Mojtabie et al 2003; Opolka et al 2003; Gibson et al 2004), 
our study expands the literature by showing differential 
adherence among 4 atypical agents and a descending order 
in adherence levels: clozapine, olanzapine, risperidone, and 
quetiapine, with similar and intermediate levels of adherence 
for risperidone- and quetiapine-treated patients. Moreover, 
haloperidol was associated with the poorest level of adher-
ence and persistence despite its use in moderate doses 
(mean dose 8.8 mg/day). This is of interest because most 
industry-sponsored clinical trials have compared atypical 
antipsychotics with haloperidol in higher doses, a practice 
that was considered by some (Geddes et al 2000; Rosenheck 
2005) to have biased the results in favor of the newer agents. 
The present ﬁ  ndings appear consistent with the meta-analysis 
by Davis et al (2003), which showed that the dose of halo-
peridol did not bias the ﬁ  ndings that favored the atypicals 
over the typicals.
Table 3 Differences between treatment groups on proportion of adherent patients using 8 different MPR thresholds to deﬁ  ne 
adherence
Treatment groups  MPR threshold (%)
   60%   65%   70%   75%   80%   85%   90%   95%
Atypicals, combined vs HAL  67.7c 66.0c 64.1c 62.8c 61.1c 59.2c 57.8c 56.5c
  42.7 41.8 38.2  37.3  34.5 29.1 29.1 24.5
OLZ vs RIS  70.9  69.2a 67.1a 65.4a 63.7a 62.2a 60.8a 58.8
  64.7  62.1  59.6 58.3 56.6  54  53.2  51.9
OLZ vs QUE  70.9b 69.2a 67.1a 65.4a 63.7a 62.2a 60.8a 58.8a
  56.3 56.3 54.5  54.5  51.8 49.1 46.4 46.4
RIS vs QUE  64.7  62.1  59.6  58.3  56.6  54  53.2  51.9
  56.3 56.3 54.5  54.5  51.8 49.1 46.4 46.4
CLO vs HAL  79.7c 78.4c 78.4c 77c 77c 77c 75.7c 75.7c
  42.7 41.8 38.2  37.3  34.5 29.1 29.1 24.5
CLO vs RIS  79.7a 78.4a 78.4a 77b 77b 77b 75.7b 75.7b
  64.7  62.1  59.6 58.3 56.6  54  53.2  51.9
CLO vs OLZ  79.7  78.4  78.4  77  77  77  75.7  75.7a
  70.9 69.2 67.1  65.4  63.7 62.2 60.8 58.8
CLO vs QUE  79.7b 78.4a 78.4b 77a 77b 77b 75.7b 75.7b
  56.3 56.3 54.5  54.5  51.8 49.1 46.4 46.4
Sample size: Haloperidol n = 110; OLZ n = 347; RIS n = 235; QUE n = 112; CLO n = 74.
aSigniﬁ  cant groups difference at p   0.05.
bSigniﬁ  cant groups difference at p   0.01.
cSigniﬁ  cant groups difference at p   0.001.
Abbreviations: MPR, medication possession ratio; CLO, clozapine; HAL, haloperidol; OLZ, olanzapine; QUE, quetiapine; RIS, risperidone.Patient Preferences and Adherence 2008:2 74
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While haloperidol was prescribed in moderate doses, 
quetiapine was prescribed in relatively low doses (mean 
331.6 mg/day). This dose appears, however, to reﬂ  ect medi-
cation use pattern of quetiapine in usual practice in the US. 
This was previously shown in a large claims database study 
of schizophrenia patients treated in the US (Gianfrancesco 
et al 2006) that was sponsored by the manufacturer of que-
tiapine. Using 7017 treatment episodes during a period from 
January 1999 through August 2003, the study reported the 
mean dose of quetiapine to be 264 mg/day, suggesting that 
our ﬁ  ndings reﬂ  ect usual treatment pattern with quetiapine 
in the US, at least during the study period.
Although the current adherence-related findings are 
consistent with several previous studies, they are also incon-
sistent with some others (Dolder et al 2002; Søholm and 
Lublin 2003; Gilmer et al 2004; Valenstein et al 2004; Joyce 
et al 2005; Gianfrancesco et al 2006). The reasons for the 
inconsistent ﬁ  ndings are unclear, but may stem from meth-
odological issues such as differences in adherence measures, 
study designs, patient populations, cross-sectional approach 
that compares treatment groups independently of the time 
of initiation on the medication, lack of uniform period of 
follow-up, and use of different approaches to controlling for 
selection effects, and the potential pre-existing differences 
between the treatment groups.
The present study also shows – for the ﬁ  rst time – a high 
and signiﬁ  cant level of concordance between adherence 
and persistence with the medication in the same population, 
suggesting that the two measures may be interchangeable. 
It is unclear, however, if both parameters are indeed measuring 
the same thing, since we used a proxy measure of adherence 
(did not observe if patients were taking the medications as 
directed in the prescribed dosage, schedule, and method of 
ingestion) and did not assess medication acceptance, which 
may impact both adherence and persistence.
Mirroring results from the adherence-based analyses, 
persistence level was poorer with haloperidol compared to 
the four combined atypicals with a similar descending order 
in persistence levels: clozapine, olanzapine, risperidone, 
quetiapine, and haloperidol, and with similar and intermedi-
ate levels of persistence for the risperidone- and quetiapine-
treatment groups. These ﬁ  ndings are consistent with previous 
research demonstrating better persistence with clozapine 
(Ascher-Svanum et al 2006b; McEvoy et al 2006; Haro et al 
2007) compared to olanzapine, risperidone, quetiapine, and 
typical antipsychotics and better persistence with olanzapine 
compared to haloperidol (Revicki et al 1999; Glick and Berg 
2002; Ren et al 2002; Lieberman et al 2003; Dossenbach 
et al 2004; Tiihonen et al 2006; Ascher-Svanum et al 2006b; 
Tunis et al 2006), risperidone (Gilbody et al 2000; Bagnall 
et al 2003; Leucht et al 2003; Santarlasci and Messori 2003; 
Dossenbach et al 2004; Pelagotti et al 2004; Breier et al 2005; 
Lieberman et al 2005; Ascher-Svanum et al 2006b; Beasley 
et al 2007; Cooper et al 2007; Haro et al 2007; Jayaram et al 
2007; Tunis et al 2006; Beasley et al 2007; Haro et al 2007), 
and quetiapine (Dossenbach et al 2004; Lieberman 2005; 
Ascher-Svanum et al 2006b; Kinon et al 2006b; McEvoy et al 
2006; Stroup et al 2006; Beasley et al 2007; Haro et al 2007; 
Mullins et al 2007). Furthermore, as we hypothesized based 
on CATIE phase 1 ﬁ  ndings (Lieberman et al 2005), no sig-
niﬁ  cant differences were found on persistence or adherence 
between the risperidone and quetiapine treatment groups.
The observed concordance between adherence and 
persistence with antipsychotics has important ramiﬁ  cations 
for schizophrenia research and for clinical practice due to 
growing recognition that persistence with antipsychotics 
is a global proxy measure of a medication’s effectiveness 
(Lieberman et al 2005) and more importantly because both 
medication adherence and persistence are associated with 
beneﬁ  cial outcomes in the long-term treatment of patients 
with schizophrenia. Furthermore, the favorable outcomes 
associated with medication adherence are likely applicable 
to ﬁ  ndings of persistence studies. This extrapolation needs, 
however, to be further studied across adherence measures, 
beyond the MPR measure.
The strengths of our study appear to lie in its large, 
diverse, and representative sample; the ability to provide 
comparative data on a number of commonly used antipsy-
chotics; the availability of medication information during 
hospitalizations (a type of data that is typically absent in 
claims databases); and notably, the ability to generalize the 
ﬁ  ndings to patients treated in large public systems of care 
across the US.
Our study has, however, a number of limitations. First is 
the potential for selection bias due to the naturalistic, nonran-
domized design of the study in which the treatment groups 
signiﬁ  cantly differed on a number of variables at the time 
of initiation of the medication. Despite our use of statistical 
adjustments for observed group differences, other residual 
imbalances due to unobservable factors could have been pres-
ent and hampered the comparisons. Although we cannot elimi-
nate the possibility of selection bias, it is important to note that 
the current ﬁ  ndings are consistent with a large body of prior 
research – about 29 studies – that differs in study design and 
world geographies and include the NIMH-sponsored CATIE 
(Lieberman et al 2005; McEvoy 2006; Stroup et al 2006) as Patient Preferences and Adherence 2008:2 75
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well as other randomized, double-blind, controlled trials in 
which selection bias is largely eliminated (Revicki et al 1999; 
Santarlasci and Messori 2003; Kemmler et al 2005; Beasley 
et al 2007; Jayaram et al 2007; Kinon et al 2006a, b).
Lack of information about the reasons for medication 
discontinuation is another study limitation. Our study was not 
designed to assess reasons for initiation or discontinuation 
of the antipsychotic medications, thus lacking this clinically 
important information. It is notable, however, that time 
to medication discontinuation for any cause was chosen 
by the NIMH-Sponsored CATIE trials to be the primary 
outcome measure, as this global index is said to reﬂ  ect a 
medication efﬁ  cacy, safety, and tolerability from both patient 
and clinician perspectives (Stroup et al 2003; Lieberman 
et al 2005).
Another study limitation is the use of prescription, rather 
than pharmacy ﬁ  ll data to assess adherence and persistence. 
Previous research (Svarstad et al 2001) has demonstrated, 
however, a high level of agreement between prescription 
rate and pharmacy ﬁ  ll rate in this severely ill population. 
Moreover, several MPR ﬁ  ndings in the present prescription-
based study were consistent with pharmacy ﬁ  ll-based MPR 
ﬁ  ndings in previous studies (Svarstad et al 2001; Zhao et al 
2002; Opolka et al 2003; Rascati et al 2003; Gibson et al 
2004), suggesting that the two measures are highly correlated. 
Of special note is a study of Michigan Medicaid pharmacy 
database (Gibson et al 2004) showing higher adherence rates 
for olanzapine- than risperidone-treated patients (60% vs 54%, 
p   0.01), a ﬁ  nding that was almost identical to ours (63.7% 
vs 56.6%, p   0.05). That study also reported an adherence 
rate on haloperidol (37%) that was very similar to that found 
in the current study (34.5%). Thus, although the current 
analysis used prescription data, results were similar to those 
based on pharmacy ﬁ  ll data, helping to bolster conﬁ  dence 
in the validity of the current ﬁ  ndings. An additional study 
limitation is lack of control for potential “sponsor” bias that 
could have inﬂ  uenced clinicians’ medication use patterns in 
favor of the sponsor’s antipsychotic medication (olanzapine). 
Although we cannot rule out this possibility, the results of 
the present study are consistent with previous results reported 
by researchers who used nonindustry-sponsored data such as 
Medicaid claims databases (Opolka et al 2003; Rascati et al 
2003; Gibson et al 2004) and with results from independent, 
nonindustry-sponsored studies (Gilbody et al 2000; Bagnall 
et al 2003; Leucht et al 2003; Kemmler et al 2005; Lieberman 
2005; Cooper et al 2007).
Current ﬁ  ndings demonstrate that atypical agents are not 
all alike on medication adherence and persistence suggesting 
that the choice of antipsychotic agent may be an important 
factor that impacts treatment adherence and persistence, 
thus the long-term treatment outcomes during usual care 
of patients with schizophrenia. Although this study found 
better adherence and persistence with atypicals, and among 
the atypicals with clozapine and olanzapine, it is important 
to note that at its best the overall level of adherence (and 
persistence) with the medication was still suboptimal, thus 
requiring diligent identification of the poorly adherent 
patients and the provision of relevant and effective adher-
ence interventions to help enhance these patients’ long-term 
outcomes. Current ﬁ  ndings are based on a large and diverse 
group of patients that varied in health care delivery systems, 
geography, ethnicity, gender, and illness severity, a diversity 
that may facilitate generalization of the ﬁ  ndings to schizo-
phrenia patients treated across the US. Future studies are 
needed to replicate the ﬁ  ndings and to identify the reasons 
that drive better adherence and persistence with speciﬁ  c 
antipsychotics in order to help tailor individualized adherence 
improvement strategies for patients who are poorly adherent 
with their antipsychotic regimens.
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